they are affiliated with (if any), and an email address prior to placing callers into the conference call. Callers can expect to incur charges for calls they initiate over wireless lines, and the Commission will not refund any incurred charges. Callers will incur no charge for calls they initiate over landline connections to the toll-free telephone number. Persons with hearing impairments may also follow the proceedings by first calling the Federal Relay Service at 1–800–977–8339 and providing the Service with the conference call number and conference ID number.

Members of the public are also entitled to submit written comments: the comments must be received in the regional office within 30 days following the meeting. Written comments may be mailed to the Regional Program Unit Office, U.S. Commission on Civil Rights, 230 S. Dearborn, Suite 2120, Chicago, IL 60604. They may also be faxed to the Commission at (312) 353–8324, or emailed to Regional Director, Jeffrey Hinton at jhinton@usccr.gov. Persons who desire additional information may contact the Regional Program Unit Office at (312) 353–8311.

Records generated from this meeting may be inspected and reproduced at the Regional Program Unit, as they become available, both before and after the meeting. Records of the meeting will be available via www.facadatabase.gov under the Commission on Civil Rights, South Carolina Advisory Committee link. Persons interested in the work of this Committee are directed to the Commission’s website, http://www.usccr.gov, or may contact the Southern Regional Office at the above email or street address.

**Agenda**

Welcome and Introductions

Dr. Geoffrey Alpert, University of South Carolina, Department of Criminology and Criminal Justice

Discussion on Policing Project

Open Comment

Adjournment

Dated: September 18, 2018.

David Mussatt,

Supervisory Chief, Regional Programs Unit.

[FR Doc. 2018–20596 Filed 9–20–18; 8:45 am]

1 See Sodium Gluconate, Gluconic Acid, and Derivative Products from the People’s Republic of China: Preliminary Determination of Sales at Less Than Fair Value (July 10, 2018) (Preliminary Determination) and accompanying Preliminary Decision Memorandum.


**DEPARTMENT OF COMMERCE**

**International Trade Administration**

[A–570–071]

**Sodium Gluconate, Gluconic Acid, and Derivative Products From the People’s Republic of China: Final Affirmative Determination of Sales at Less Than Fair Value**

**AGENCY:** Enforcement and Compliance, International Trade Administration, Department of Commerce.

**SUMMARY:** The Department of Commerce (Commerce) determines that sodium gluconate, gluconic acid, and derivative products from the People’s Republic of China (China) are being sold in the United States at less than fair value (LTFV).

**DATES:** Applicable September 21, 2018.

**FOR FURTHER INFORMATION CONTACT:** Magd Zalok or Stephen Bailey, AD/CVD Operations, Office IV, Enforcement and Compliance, International Trade Administration, U.S. Department of Commerce, 1401 Constitution Avenue NW, Washington, DC 20230; telephone: (202) 482–4162 or (202) 482–0193, respectively.

**SUPPLEMENTARY INFORMATION:**

**Background**

This final determination is made in accordance with section 735(a) of the Tariff Act of 1930, as amended (the Act). On July 10, 2018, Commerce published in the Federal Register its preliminary affirmative determination of sales at LTFV investigation of sodium gluconate, gluconic acid, and derivative products from China. We invited interested parties to comment on the Preliminary Determination. On August 9, 2018, we received a case brief from PMP Fermentation Products, Inc., the petitioner in this investigation. We received no comments from other interested parties.

For a complete description of the events that followed the Preliminary Determination, as well as a full discussion of the issues raised by parties for this final determination, see the Issues and Decision Memorandum that is dated concurrently with this determination and hereby adopted by this notice. The Issues and Decision Memorandum is a public document and is on file electronically via Enforcement and Compliance’s Antidumping and Countervailing Duty Centralized Electronic Service System (ACCESS). ACCESS is available to registered users at http://access.trade.gov, and is available to all parties in the Central Records Unit, Room B8024 of the main Department of Commerce building. In addition, a complete version of the Issues and Decision Memorandum can be accessed directly at http://enforcement.trade.gov/frn/. The signed Issues and Decision Memorandum and the electronic version are identical in content.

**Scope of the Investigation**

The products covered by this investigation are sodium gluconate, gluconic acid, and derivative products from China. For a complete description of the scope of this investigation, see Appendix I to this notice.

No interested party commented on the scope published in the Preliminary Determination. Thus, Commerce has made no changes to the scope of the investigation from that published in the Initiation Notice and Preliminary Determination.

**Period of Investigation**

The period of investigation is April 1, 2017, through September 30, 2017.

**Analysis of Comments Received**

All issues raised in the case brief that was submitted by the petitioner in this investigation are addressed in the Issues and Decision Memorandum. A list of the issues addressed in the Issues and Decision Memorandum is attached to this notice at Appendix II.

**China-Wide Entity**

For the reasons explained in the Preliminary Determination, we are continuing to find that the use of adverse facts available (AFA), pursuant to sections 776(a) and (b) of the Act, is appropriate and are applying a rate based entirely on AFA to the China-wide entity. The China-wide entity includes Shandong Fuyang Biotechnology Co., Ltd./Shandong Fuyang Biology Starch Co., Ltd.

1 See Sodium Gluconate, Gluconic Acid, and Derivative Products from France and the People’s Republic of China: Final Affirmative Determination of Sales at Less Than Fair Value, 83 FR 31949 (July 10, 2018) (Preliminary Determination) and accompanying Preliminary Decision Memorandum.

(Shandong Fuyang), Qingdao Dongxiao Enterprise Co., Ltd. (Qingdao Dongxiao), Zheljiang Tianyi Food Additives Co., Ltd. (Tianyi Food), and Dezhou Huiyang Biotechnology Co., Ltd. (Dezhou Huiyang). These companies failed to respond to Commerce’s requests for information and withdrew from participation in this investigation. As these non-responsive companies did not demonstrate that they are eligible for separate rate status, Commerce continues to consider them to be part of the China-wide entity. Consequently, we continue to find that the China-wide entity, which includes these non-responsive companies, withheld requested information, significantly impeded this proceeding and failed to cooperate to the best of its ability.

**China-Wide Rate**

In selecting the AFA rate for the China-wide entity, Commerce’s practice is to select a rate that is sufficiently adverse to ensure that the uncooperative party does not obtain a more favorable result by failing to cooperate than if it had fully cooperated. Specifically, it is Commerce’s practice to select, as an AFA rate, the higher of: (a) The highest dumping margin alleged in the petition; or (b) the highest calculated dumping margin of any respondent in the investigation. There are no respondents for which we are calculating a separate dumping margin for the final determination. Thus, the highest (and only) rate on the record of the proceeding is the rate found in the Petition, which is the only information reasonably at Commerce’s disposal to determine a rate that is sufficiently adverse to induce cooperation.

Thus, as AFA, Commerce assigned to the China-wide entity the rate of 213.15 percent, which is the sole dumping margin alleged in the Petition.

---

### Separate Rates

For the final determination, we continue to find that the evidence placed on the record of this investigation by Anhui Xingzhou Medicine Food Co., Ltd. (Xingzhou Medicine) demonstrates an absence of de jure and de facto government control. Accordingly, consistent with its Preliminary Determination, Commerce assigned Xingzhou Medicine a separate rate, which is the petition rate, because it is the only rate available on the record of this proceeding. For a full description of the methodology underlying Commerce’s final determination, see the Issues and Decision Memorandum.

### Combination Rates

In the Initiation Notice, Commerce stated that it would calculate producer/exporter combination rates for the respondents that are eligible for a separate rate in this investigation. Policy Bulletin 05.1 describes this practice. Because Commerce determined that the mandatory respondents originally selected are not eligible for separate rate status and, thus, should be considered part of the China-wide entity and assigned, as AFA, the petition rate to the China-wide entity, Commerce did not calculate producer/exporter combination rates for those respondents.

### Final Determination

Commerce determines that sodium gluconate, gluconic acid, and derivative products from China are being, or are likely to be, sold in the United States at LTFV, and that the following dumping margins exist:

<table>
<thead>
<tr>
<th>Exporter</th>
<th>Producer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anhui Xingzhou Medicine Food Co., Ltd</td>
<td>Xiwang Pharmaceutical Co., Ltd</td>
</tr>
<tr>
<td>Anhui Xingzhou Medicine Food Co., Ltd</td>
<td>Zhucheng Shuguang Biotech Co., Ltd</td>
</tr>
<tr>
<td>China-wide Entity</td>
<td></td>
</tr>
</tbody>
</table>

---

15 See Initiation Notice, 83 FR 516.
17 The China-wide Entity includes Dezhou Huiyang, Qingdao Dongxiao, Shandong Fuyang, and Tianyi Food.
Disclosure

Normally, Commerce discloses to interested parties the calculations performed in connection with a final determination within five days of any public announcement or, if there is no such announcement, within five days of the date of publication of the notice of final determination in the Federal Register, in accordance with 19 CFR 351.224(b). However, because Commerce applied AFA to the China-wide entity (which includes the companies subject to individual examination) in this investigation, in accordance with section 776 of the Act, and the applied AFA rate is based solely on the Petition, there are no calculations to disclose.

Continuation of Suspension of Liquidation

In accordance with section 735(c)(1)(B) of the Act, we will direct U.S. Customs and Border Protection (CBP) to continue to suspend liquidation of all entries of sodium gluconate, gluconic acid, and derivative products from China, as described in Appendix I of this notice, which are entered, or withdrawn from warehouse, for consumption on or after July 10, 2018, the date of publication in the Federal Register of the affirmative Preliminary Determination.

Further, pursuant to section 735(c)(1)(B)(ii) of the Act, Commerce will instruct CBP to collect a cash deposit as follows: (1) The rate for the exporters listed in the chart above will be the rate we have determined in this final determination; (2) for all Chinese exporters of subject merchandise which have not received their own rate, the cash-deposit rate will be the China-wide rate; and (3) for all non-Chinese exporters of subject merchandise which have not received their own rate, the cash-deposit rate will be the rate applicable to the Chinese exporter/producer combination that supplied that non-Chinese exporter. These suspension-of-liquidation instructions will remain in effect until further notice. Because there has been no demonstration that an adjustment for domestic subsidies is warranted, Commerce has not made any such adjustment to the rate assigned to Xingzhout Medicine or the China-wide entity. Additionally, Commerce is making no adjustments for export subsidies to the antidumping cash deposit rate in this investigation because we have made no findings in the companion countervailing duty investigation that any of the programs are export subsidies.18

International Trade Commission Notification

In accordance with section 735(d) of the Act, we intend to notify the International Trade Commission (ITC) of the final affirmative determination of sales at LTFV. As Commerce’s final determination is affirmative, in accordance with section 735(b)(2) of the Act, the ITC will determine, within 45 days, whether the domestic industry, in the United States is materially injured, or threatened with material injury, by reason of imports of sodium gluconate, gluconic acid, and derivative products from China, or sales (or the likelihood of sales) for importation, of sodium gluconate, gluconic acid, and derivative products from China. If the ITC determines that such injury does not exist, this proceeding will be terminated, and all securities posted will be refunded or canceled. If the ITC determines that such injury does exist, Commerce intends to issue an antidumping duty order directing CBP to assess, upon further instruction by Commerce, antidumping duties on all imports of the subject merchandise entered, or withdrawn from warehouse, for consumption on or after the effective date of the suspension of liquidation.

Notification Regarding Administrative Protective Orders

This notice will serve as a reminder to the parties subject to administrative protective order (APO) of their responsibility concerning the disposition of propriety information disclosed under APO in accordance with 19 CFR 351.305. Timely written notification of return or destruction of APO materials or conversion to judicial protective order is hereby requested. Failure to comply with the regulations and terms of an APO is a sanctionable violation.

We intend to issue and publish this determination in accordance with sections 735(d) and 777(i)(1) of the Act.

Dated: September 17, 2018.

Gary Taverman,
Deputy Assistant Secretary for Antidumping and Countervailing Duty Operations, performing the non-exclusive functions and duties of the Assistant Secretary for Enforcement and Compliance.

Appendix I

Scope of the Investigation

The scope of the investigation covers all grades of sodium gluconate, gluconic acid, liquid gluconate, and glucono delta lactone (GDL) (collectively GNA Products), regardless of physical form (including, but not limited to substrates; solutions; dry granular form or powders, regardless of particle size; or as a slurry). The scope also includes GNA Products that have been blended or are in solution with other product(s) where the resulting mix contains 35 percent or more of sodium gluconate, gluconic acid, liquid gluconate, and/or GDL by dry weight.

Sodium gluconate has a molecular formula of NaC\textsubscript{6}H\textsubscript{12}O\textsubscript{7}. Sodium gluconate has a Chemical Abstract Service (CAS) registry number of 527–07–1, and can also be called “sodium salt of gluconic acid” and/or sodium 2, 3, 4, 5, 6-pentahydroxyhexanoate. Gluconic acid has a molecular formula of C\textsubscript{6}H\textsubscript{10}O\textsubscript{6}. Gluconic acid has a CAS registry number of 526–95–4, and can also be called 2, 3, 4, 5, 6-pentahydroxyhexanocaproic acid. Liquid gluconate is a blend consisting of liquid gluconic acid and sodium gluconate in an aqueous solution. Liquid gluconate has CAS registry numbers of 527–07–1, 526–95–4, and 7732–18–5, and can also be called 2, 3, 4, 5, 6-pentahydroxyhexanocaproic acid-hexanoate. GDL has a molecular formula of NaC\textsubscript{6}H\textsubscript{10}O\textsubscript{7}. GDL has a CAS registry number of 90–80–2, and can also be called d-glucono-1,5-lactone.

The merchandise covered by the scope of the investigation is currently classified in the Harmonized Tariff Schedule of the United States (HTSUS) under subheadings 2918.16.1000, 2918.16.5010, and 3923.20.5020. Merchandise covered by the scope may also enter under HTSUS subheadings 2918.16.1000, 3824.99.2890, and 3824.99.9295. Although the HTSUS subheadings and CAS registry numbers are provided for convenience and customs purposes, the written description of the merchandise is dispositive.

Appendix II

List of Topics Discussed in the Issues and Decision Memorandum

I. Summary
II. List of Issues
III. Background
IV. Scope of Investigation
V. Discussion of the Issues
Comment 1: Application of Adverse Facts Available (AFA) to the China-wide Entity
Comment 2: Whether to Assign the China-wide Entity Rate to the Separate Rate Applicant
Comment 3: Whether the Scope of the Investigation Should be Modified
VI. Recommendation

DEPARTMENT OF COMMERCE
International Trade Administration
[C–570–072]

Sodium Gluconate, Gluconic Acid and Derivative Products From the People’s Republic of China: Final Affirmative Countervailing Duty Determination

AGENCY: Enforcement and Compliance, International Trade Administration, Department of Commerce.

SUMMARY: The Department of Commerce (Commerce) determines that countervailable subsidies are being provided to producers and exporters of sodium gluconate, gluconic acid and derivative products from the People’s Republic of China (China).


FOR FURTHER INFORMATION CONTACT: Robert Galantucci or Jonathan Hill, AD/CVD Operations, Office IV, Enforcement and Compliance, International Trade Administration, U.S. Department of Commerce, 1401 Constitution Avenue NW, Washington, DC 20230; telephone (202) 482–2923 or (202) 482–3518, respectively.

SUPPLEMENTARY INFORMATION:

Background

This final determination is made in accordance with section 705 of the Tariff Act of 1930, as amended (the Act). The petition in this investigation is PMP Fermentation Products, Inc. (the petitioner). The mandatory respondents in this investigation are Qingdao Dongxiao Enterprise Co., Ltd. (Qingdao Dongxiao), Shandong Fuyang Biotechnology Co. (Fuyang), Shandong Kaison Biochemical Co. Ltd (Kaison), and Tongxiang Hongyu Chemical Co., Ltd. (Hongyu Chemical). Kaison, and Qingdao Dongxiao did not respond to any of our requests for information.

We published our Preliminary Determination on May 23, 2018. On May 30, 2018, Fuyang, the sole respondent to provide a questionnaire response in this investigation, notified Commerce that it would no longer be participating in the proceeding. On June 21, 2018, the petitioner submitted a case brief. We received no comments from other interested parties.

Additional background on this case, including a summary of events that occurred since Commerce published the Preliminary Determination, and a discussion of comments from the petitioner, are provided in the Issues and Decision Memorandum, which is hereby adopted by this notice. The Issues and Decision Memorandum is a public document and is on file electronically via Enforcement and Compliance’s Antidumping and Countervailing Duty Centralized Electronic Service System (ACCESS). ACCESS is available to registered users at https://access.trade.gov and is available to all parties in the Central Records Unit, room B8024 of the main Department of Commerce building. In addition, a complete version of the Issues and Decision Memorandum can be accessed directly at http://enforcement.trade.gov. The signed and electronic versions of the Issues and Decision Memorandum are identical in content.

Scope of the Investigation

The products covered by this investigation are sodium gluconate, gluconic acid, and derivative products from China. We have made no changes to the scope of the investigation, as published in the Preliminary Determination. For a complete description of the scope of this investigation, see Appendix I to this notice.

Period of Investigation

The period of investigation is January 1, 2016, through December 31, 2016.

Analysis of Comments Received

All issues raised in the case brief submitted by the petitioner are addressed in the Issues and Decision Memorandum accompanying this notice. A list of the issues addressed in the memorandum is attached to this notice at Appendix II.

Adverse Facts Available

In this final determination, we continue to apply facts available with an adverse inference to Fuyang, Hongyu Chemical, Kaison, and Qingdao Dongxiao. For purposes of this final determination, we relied on facts available and, because the respondents did not respond, or did not act to the best of their ability in responding to our requests for information, we drew adverse inferences in selecting from among the facts otherwise available, pursuant to sections 776(a)–(b) of the Act. A detailed discussion of our application of adverse facts available was provided in the Preliminary Decision Memorandum accompanying our Preliminary Determination, and additional discussion is contained in the Issues and Decision Memorandum accompanying this notice.

Changes Since the Preliminary Determination

In our Preliminary Determination, we applied adverse facts available to calculate the subsidy rates for all mandatory respondents. We have made no changes to our analysis, or to the respondents’ subsidy rates, for this final determination.

Final Determination

With respect to the “all-others” rate, section 705(c)(5)(A)(ii) of the Act provides that if the countervailing duty rates established for all exporters and producers individually investigated are determined entirely in accordance with section 776 of the Act, Commerce may use any reasonable method to establish an all-others rate for exporters and producers not individually investigated. In this case, the rates assigned to Fuyang, Hongyu Chemical, Kaison, and

4 See Memorandum, “Issues and Decision Memorandum for the Final Affirmative Determination in the Countervailing Duty Investigation of Sodium Gluconate, Gluconic Acid and Derivative Products from the People’s Republic of China,” dated concurrently with, and hereby adopted by, this notice (Issues and Decision Memorandum).
5 See 83 FR at 23888 (noting that Commerce would consider scope comments from interested parties and implement any changes to the scope in the final countervailing duty determination).
6 See sections 776(a) and (b) of the Act. Section 782(i) of the Act requires Commerce to verify a respondent’s data as part of an investigation. However, because we applied adverse facts available to each of the respondents in the Preliminary Determination, we did not conduct verification in this investigation.